Many type 2 diabetics are shifting towards the use of insulin along with their oral treatment. In 2006, 43.0 per cent of type II diabetics were using the more expensive insulin in addition to the oral treatment. This trend is
Pharmatest Services a full-service Contract Research Organization (CRO) announces today that it has signed new customer contracts valued at nearly US$700,000 during the first quarter of 2008 with multiple leading biopharmaceutical companies worldwide. The new contracts include research projects in
Pharmagel Engineering develops Softgel Technology for pharmaceutical, nutraceutical and cosmetic products.SOFTGELThe softgel (soft gelatine) capsule is a one piece, hermetically sealed shell wall filled with oils and non-acqueos liquids, plus solids in a paste or solution form.The shell gives a
Medicare proposes new way to protect Medicare beneficiaries in Medicare Advantage and Prescription Drug Programs and tightens marketing standards protecting beneficiaries from inappropriate cost sharing.
University Health Industries, Inc., (OTC:UVHI) a Florida corporation engaged in the development, marketing and sale of proprietary, patent-pending nutraceutical products, including its leading brands Arthroleve(TM) and Zenstral PMS(TM), announces new name and ticker symbol. (PRWeb May 9, 2008) Read the
There was a huge buzz across the UK as people voted in their thousands to push Beth Cameron, from Gullane Primary School, over the finishing line in a national competition to design the official logo for Malaria Awareness Week 2008
www.MedicalDeviceGuru.com is a Medical Technology Forum for Healthcare Industry Professionals which contains on-demand content in Orthopedics, Cardiovascular, Robotics, Medical Imaging, Pharmaceutical & Biotech, MIS and Med Device. A "Careers" section includes "The Medical Device Interview Prep Guide" and thousands of
This report on prescription drug rebates details how they have evolved over the years and continue to change. It also examines how the health care industry has reacted to new reimbursement methodologies, and details strategies that have been successful, as
90% of the illicit sites tracked by KnujOn.com are clustered at just 20 registrars which is only 2.5% of the entire registrar population. While networks of compromised spam generators, "bot-nets" are large and millions of spam emails are constantly sent,
A one-day program that takes you through the process of discovery, preclinical and clinical development, and product registration (PRWeb May 11, 2008) Read the full story at http://ww1.prweb.com/releases/2008/05/prweb931274.htm
Bridgelogix, the premier data collection solution for the Infor Baan community announces 2007 as a record year, expanding to 32 countries and 1,000+ users. (PRWeb May 11, 2008) Read the full story at http://ww1.prweb.com/releases/2008/05/prweb931594.htm
LifeCycle Pharma has announced positive results from the company's Phase II clinical program with LCP-AtorFen, a fixed-dose combination product of atorvastatin and fenofibrate for the treatment of mixed dyslipidemia.
The FDA has reported that it will expand its post marketing safety activities, and adopt new scientific approaches to drug safety to meet its commitments under the Prescription Drug User Fee Act.
Osiris Therapeutics has received clearance from the FDA to initiate an expanded access treatment program for Prochymal, making the investigational stem cell product available to children with life-threatening graft versus host disease.
BiPar Sciences has announced the expansion of Phase II clinical trial programs for its lead product, BSI-201, in ovarian cancer. This is the third major clinical trial of BSI-201 that BiPar has launched in the past six months, expanding on
Dor BioPharma has entered into a one-year exclusive option with the president and Fellows of Harvard College to license analogues of anthrax toxin for prospective use in vaccines against anthrax, a potentially fatal disease caused by the spore-forming, gram-positive bacterium
Specialty pharmaceutical firm Uluru has announced the company's launch plan for Altrazeal and the commercial availability of the product commencing the week of May 19, 2008.
EntreMed has announced that the Dana-Farber Cancer Institute has joined the University of Colorado Cancer Center in conducting a Phase I study of ENMD-2076 in advanced cancer patients.
